189 related articles for article (PubMed ID: 7037155)
1. A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy.
Balch CM; Smalley RV; Bartolucci AA; Burns D; Presant CA; Durant JR
Cancer; 1982 Mar; 49(6):1079-84. PubMed ID: 7037155
[TBL] [Abstract][Full Text] [Related]
2. A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results.
Clunie GJ; Gough IR; Dury M; Furnival CM; Bolton PM
Cancer; 1980 Aug; 46(3):475-9. PubMed ID: 6994866
[TBL] [Abstract][Full Text] [Related]
3. The natural history of resectable metastatic melanoma (Stage IVA melanoma).
Feun LG; Gutterman J; Burgess MA; Hersh EM; Mavligit G; McBride CM; Benjamin RS; Richman SP; Murphy WK; Bodey GP; Brown BW; Mountain CF; Leavens ME; Freireich EJ
Cancer; 1982 Oct; 50(8):1656-63. PubMed ID: 7116298
[TBL] [Abstract][Full Text] [Related]
4. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
Thatcher N; Mene A; Banerjee SS; Craig P; Gleave N; Orton C
Br J Surg; 1986 Feb; 73(2):111-5. PubMed ID: 3512025
[TBL] [Abstract][Full Text] [Related]
5. The impact of surgical quality control in multi-institutional group trials involving adjuvant cancer treatments.
Balch CM; Durant JR; Bartolucci AA
Ann Surg; 1983 Aug; 198(2):164-7. PubMed ID: 6347102
[TBL] [Abstract][Full Text] [Related]
6. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
[TBL] [Abstract][Full Text] [Related]
7. Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum.
Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Braun DW; Fortner JG; Oettgen HF
Cancer; 1981 Jul; 48(2):245-51. PubMed ID: 7016302
[TBL] [Abstract][Full Text] [Related]
8. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
Balch CM; Murray D; Presant C; Bartolucci AA
Surgery; 1984 Apr; 95(4):454-9. PubMed ID: 6369594
[TBL] [Abstract][Full Text] [Related]
9. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA
J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856
[TBL] [Abstract][Full Text] [Related]
10. The role of adjuvant therapy in melanoma management.
Barth A; Morton DL
Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial.
Hersey P; Coates AS; McCarthy WH; Thompson JF; Sillar RW; McLeod R; Gill PG; Coventry BJ; McMullen A; Dillon H; Simes RJ
J Clin Oncol; 2002 Oct; 20(20):4181-90. PubMed ID: 12377961
[TBL] [Abstract][Full Text] [Related]
13. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.
Wallack MK; Sivanandham M; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty L; Richards JM; Bartolucci AA; Rosen L
J Am Coll Surg; 1998 Jul; 187(1):69-77; discussion 77-9. PubMed ID: 9660028
[TBL] [Abstract][Full Text] [Related]
14. Melanoma of the ear: prognostic factors and surgical strategies.
Jahn V; Breuninger H; Garbe C; Moehrle M
Br J Dermatol; 2006 Feb; 154(2):310-8. PubMed ID: 16433802
[TBL] [Abstract][Full Text] [Related]
15. Chemoimmunotherapy in disseminated melanoma and colorectal carcinoma.
Gough IR; Bolton PM; Clunie GJ; Burnett W
Aust N Z J Surg; 1978 Jun; 48(3):296-300. PubMed ID: 281221
[TBL] [Abstract][Full Text] [Related]
16. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia.
Balch CM; Soong SJ; Milton GW; Shaw HM; McGovern VJ; Murad TM; McCarthy WH; Maddox WA
Ann Surg; 1982 Dec; 196(6):677-84. PubMed ID: 7149819
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
18. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
Karakousis CP; Didolkar MS; Lopez R; Baffi R; Moore R; Holyoke ED
Cancer Treat Rep; 1979; 63(11-12):1739-43. PubMed ID: 393377
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of transfer factor in Stage II malignant melanoma.
Bukowski RM; Deodhar S; Hewlett JS; Greenstreet R
Cancer; 1983 Jan; 51(2):269-72. PubMed ID: 6336977
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.
Callender GG; Egger ME; Burton AL; Scoggins CR; Ross MI; Stromberg AJ; Hagendoorn L; Martin RC; McMasters KM
Am J Surg; 2011 Dec; 202(6):659-64; discussion 664-5. PubMed ID: 22137134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
